Table S1. The clinicopathologic characteristics of HCC patients in the test and validation cohorts.
| Variable | Test (n=505) | Validation (n=249) | P value | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | |||
| Age (y) | ||||||
| ≤50 | 183 | 36.2 | 106 | 42.6 | 0.093 | |
| >50 | 322 | 63.8 | 143 | 57.4 | ||
| Gender | ||||||
| Female | 83 | 16.4 | 28 | 11.2 | 0.059 | |
| Male | 422 | 83.6 | 221 | 88.8 | ||
| Cirrhosis | ||||||
| No | 241 | 47.7 | 119 | 47.8 | 0.986 | |
| Yes | 264 | 52.3 | 130 | 52.2 | ||
| ALB (g/dL) | ||||||
| ≤3.5 | 46 | 9.1 | 22 | 8.8 | 0.902 | |
| >3.5 | 459 | 90.9 | 227 | 91.2 | ||
| TB (µmol/L) | ||||||
| ≤17 | 399 | 79.0 | 199 | 79.9 | 0.772 | |
| >17 | 106 | 21.0 | 50 | 20.1 | ||
| HBsAg | ||||||
| Negative | 67 | 13.3 | 49 | 19.7 | 0.022 | |
| Positive | 438 | 86.7 | 200 | 80.3 | ||
| HCV | ||||||
| Negative | 438 | 86.7 | 249 | 100 | 0.000 | |
| Positive | 67 | 13.3 | 0 | 0 | ||
| AFP (ng/mL) | ||||||
| ≤20 | 249 | 49.3 | 131 | 52.6 | 0.394 | |
| >20 | 256 | 50.7 | 118 | 47.4 | ||
| Tumor number | ||||||
| Single | 447 | 88.5 | 217 | 87.1 | 0.586 | |
| Multiple | 58 | 11.5 | 32 | 12.9 | ||
| Differentiation | ||||||
| I-II | 310 | 61.4 | 159 | 63.9 | 0.511 | |
| III-IV | 195 | 38.6 | 90 | 36.1 | ||
| Encapsulation | ||||||
| None | 164 | 32.5 | 84 | 33.7 | 0.592 | |
| Yes | 341 | 67.5 | 165 | 66.3 | ||
| Tumor size (cm) | ||||||
| ≤5 | 331 | 65.5 | 160 | 64.3 | 0.727 | |
| >5 | 174 | 34.5 | 89 | 35.7 | ||
| BCLC stage | ||||||
| 0 + A | 323 | 64.0 | 157 | 63.1 | 0.038 | |
| B | 148 | 29.3 | 62 | 24.9 | ||
| C | 34 | 6.7 | 30 | 12.0 | ||
| Chinese stage* | ||||||
| Ia | 282 | 55.8 | 136 | 54.6 | 0.020 | |
| Ib | 160 | 31.7 | 60 | 24.1 | ||
| IIa | 27 | 5.3 | 22 | 8.8 | ||
| IIb | 2 | 0.4 | 1 | 0.4 | ||
| IIIa | 34 | 6.7 | 30 | 12.0 | ||
| Vascular invasion | ||||||
| No | 297 | 58.8 | 135 | 54.2 | 0.045 | |
| Micro | 174 | 34.5 | 84 | 33.7 | ||
| Macro | 34 | 6.7 | 30 | 12.0 | ||
*, Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer 2018;7:235-60. HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; ALB, albumin; AFP, α-fetoprotein; TB, total bilirubin.